glp 1 risk Benefits and Risks of GLP-1 Receptor Agonists Outlined Cardiovascular and mortality outcomes with

Exenatide once weekly plus Dapagliflozin once daily versus exenatide or Dapagliflozin alone in patients with type 2 diabetes inadequately controlled with Metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial

We may also recommend complementary therapies, such as nutrition counseling, to support your success

At higher concentrations, the peptide molecules are packed more closely together, which can increase the rate of aggregation under thermal stress

Progressive proximal muscle weakness (affecting shoulders and hips more than hands and feet) may indicate an inflammatory myopathy or other serious neuromuscular condition that requires investigation beyond simply attributing symptoms to GLP-1 therapy

Diabetes Care 2023;46:384-90.PubMed 108